Thursday, May 25, 2023 9:48:43 AM
Presentations
IR Calendar
Email Alerts
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
DOWNLOAD AS PDFMay 25, 2023
PRP Dosing Patent Validated in 12 Countries Across Europe & Method to Treat Cancer Stem Cells Receives Notice of Allowance from European Patent Office
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio made important advancements in Europe. The dosing patent, describing claims for the dosing regimen of the Company’s lead product candidate, PRP, has now been validated in 12 countries across Europe. In further news, the Company’s method to treat cancer stem cells (CSCs) using PRP received a notice of allowance from the European Patent Office (EPO). This is the third patent allowed, or granted to the Company in Europe, with further applications under examination by the EPO.
As a result of validating the dosing patent in this major global region, Propanc now has enforceable patent rights in the UK, France, Germany, Spain, Italy, Denmark, Belgium, Czech Republic, Sweden, Switzerland/ Liechtenstein and Ireland. In 2022, the worldwide pharmaceutical market was valued at approximately $1.48 trillion by Statista.com and Europe accounted for 23.4% of global pharmaceutical sales in 2021, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). As a result of validating the dosing patent across Europe, the Company’s IP portfolio has grown to 76 patents either allowed, or granted in major jurisdictions around the world.
For the allowed CSCs patent, the claims cover a method to minimize the progression of cancer in a patient who has already received a first line treatment by detecting the presence of CSCs followed by administering PRP. This patent describes the clinical application of PRP when the patient experiences a relapse and the cancer returns after primary standard of care has been applied.
“The advancement and growth of our IP portfolio represents a cornerstone for our company as we progress PRP towards entering the clinical development phase and our next major milestone,” said James Nathanielsz, BAS, MEI, Propanc’s Chief Executive Officer. “We have reached out to potential licensing partners and identified a potential suitor who expressed interest to see results from our planned Phase I, First-In-Human study in advanced cancer patients. Having an established IP portfolio with a novel, first-in-class therapy for the treatment and prevention of metastatic cancer has us well placed to seek a licensing partner for PRP, as we progress to the next major development milestones, which we hope to achieve in the not-too-distant future.”
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.
Recent PPCB News
- Biopharma on a Tear After Certificate of Grant from Japanese Patent Office • AllPennyStocks.com • 06/25/2024 04:26:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM